<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Latent <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> is associated with several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including EBV post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (LPD), Hodgkin and non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The range of expression of latent EBV antigens varies in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, which influences how susceptible the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are to immunotherapeutic approaches </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> expressing type III latency, such as in LPD, express the widest array of EBV antigens making them the most susceptible to immunotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment strategies for EBV-related <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> include restoring <z:mpath ids='MPATH_458'>normal</z:mpath> cellular immunity by adoptive immunotherapy with EBV-specific T cells and targeting the malignant B cells with monoclonal antibodies </plain></SENT>
<SENT sid="4" pm="."><plain>We review the current immunotherapies and future studies aimed at targeting EBV antigen expression in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>